Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Alpha-synuclein Stories

2012-04-18 10:46:54

Suggests way disorder progresses over time in humans Last year, researchers from the Perelman School of Medicine at the University of Pennsylvania found that small amounts of a misfolded brain protein can be taken up by healthy neurons, replicating within them to cause neurodegeneration. The protein, alpha-synuclein (a-syn), is commonly found in the brain, but forms characteristic clumps called Lewy bodies, in neurons of patients with Parkinson's disease (PD) and other neurodegenerative...

2012-04-16 23:29:44

Injection of a small amount of clumped protein triggers a cascade of events leading to a Parkinson's-like disease in mice, according to an article published online this week in the Journal of Experimental Medicine. Progressive accumulation of clumps of the protein alpha-synuclein in the brains of patients with Parkinson's disease coincides with the onset of motor dysfunction. However, whether these clumps are sufficient to trigger neurodegeneration, and how these clumps spread throughout...

2012-03-20 23:42:19

Curcumin, a compound found in the spice turmeric, is proving effective at preventing clumping of a protein involved in Parkinson´s disease, says a Michigan State University researcher. A team of researchers led by Basir Ahmad, an MSU postdoctoral researcher, demonstrated earlier this year that slow-wriggling alpha-synuclein proteins are the cause of clumping, or aggregation, which is the first step of diseases such as Parkinson´s. A new study led by Ahmad, which appears in the...

2012-02-16 09:12:00

CAMBRIDGE, Mass., Feb. 16, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting alpha-synuclein, a protein whose clumping is the pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's first grant from MJFF. "It is a privilege to collaborate with MJFF toward the development of our novel therapeutic approach. This grant will provide...

2012-02-08 10:22:40

Treatments for Parkinson's disease, estimated to affect 1 million Americans, have yet to prove effective in slowing the progression of the debilitating disease. However, University of Alabama researchers have identified how a specific gene protects dopamine-producing neurons from dying in both animal models and in cultures of human neurons, according to a scientific article publishing in the Feb. 8 edition of The Journal of Neuroscience. This increased understanding of the gene's...

2012-01-18 22:03:51

The accumulation of α-synuclein, a small, negatively charged protein, in neural cells, is one of the hallmarks of Parkinson's disease. It has been suggested that oligomeric α-synuclein causes membranes to become permeable, or to form channels on the outer cell membrane. Now, a group of scientists from Sweden has found a way to reliably replicate α-synuclein aggregation on cell membranes to investigate how different forms of α-synuclein...

2012-01-17 16:55:55

Imagine if doctors could spot Parkinson´s disease at its inception and treat the protein that triggers it before the disease can sicken the patient.   A team of researchers led by Basir Ahmad, a postdoctoral researcher at Michigan State University, has demonstrated that slow-wriggling alpha-synuclein proteins are the cause of aggregation, or clumping together, which is the first step of Parkinson´s. The results are published in the current issue of the Proceedings of the...

2011-12-16 13:59:19

Parkinson's disease is marked by the abnormal accumulation of α-synuclein and the early loss of dopamine neurons in the substantia nigra region of the brain. A polymorphism in the promotor of α-synuclein gene known as NACP-Rep1 has been implicated as a risk factor for the disease. Now, researchers have found that different variants of NACP-Rep1 and its interaction with the microtubule-associated protein tau (MAPT) H1 haplotype can influence the speed of clinical...

2011-12-01 01:47:31

New research in the FASEB Journal suggests that phosphorylated alpha-synuclein, a substance found in the blood of Parkinson's patients, could lead to definitive diagnostic tool A new research report appearing in the December issue of the FASEB Journal (http://www.fasebj.org) shows how scientists from the United Kingdom have developed a simple blood test to detect Parkinson's disease even at the earliest stages. The test is possible because scientists found a substance in the blood, called...

2011-10-12 02:00:00

NEW YORK and VIENNA, Austria, Oct. 12, 2011 /PRNewswire-USNewswire/ --The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE® PD01, a first-of-its-kind Parkinson's disease (PD) vaccine. AFFITOPE® PD01 targets and helps remove the alpha-synuclein protein, whose clumping is the pathological hallmark of PD. Principal investigator Achim...